A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

PHASE1RecruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
PharmacokineticsCardiodynamic ECGSafety, and TolerabilityGERD
Interventions
DRUG

Linaprazan glurate

"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."

DRUG

Placebo

Single dose, oral tablets

Trial Locations (1)

SE-75237

RECRUITING

CTC Clinical Trial Consultants AB, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cinclus Pharma AG

INDUSTRY